AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
AIM ImmunoTech released a virtual investor segment featuring expert insights and positive interim results for Ampligen in treating late-stage pancreatic cancer. The data from the Named Patient Program and ongoing Phase 2 trial suggest improvements in progression-free and overall survival, underlining Ampligen's potential as an immunotherapeutic opt…